Limosilactobacillus reuteri Alleviates Parkinson’s Disease by Regulating CDCA Secretion
Probiotics and Antimicrobial Proteins · 04.07.2026
DOI: 10.1007/s12602-026-11121-8 ↗Kurz gefasst
Fachartikel in der Zeitschrift Probiotics and Antimicrobial Proteins, online erschienen am 04.07.2026. Verfasst von Daidi Li und 4 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Basic Pharmacology of Ministry of Education and Joint International Research Laboratory of Ethnomedicine of Ministry of Education a…. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 33 Literaturangaben. Gefördert von: Zunyi Science and Technology Bureau, Doctor Start Fund of Zunyi Medical University, Guizhou Provincial Basic Research Programme(Natural Science).
Abstract (Originalsprache)
To explore potential therapeutic agents for Parkinson's disease (PD), we investigated the impact of Limosilactobacillus reuteri (L. reuteri), a probiotic found to be significantly depleted in 6-hydroxydopamine (6-OHDA)-induced PD rat model. Despite its known benefits, the specific effects and underlying mechanisms of L. reuteri in PD remain poorly understood. In this study, we demonstrated that supplementation with L. reuteri alleviated motor deficits and attenuated dopamine (DA) neuron damage in 6-OHDA-induced PD rats. 16 S rRNA sequencing and untargeted metabolomics revealed that L. reuteri modulated gut microbiota composition and partially restored Chenodeoxycholic acid (CDCA) levels, which were reduced in PD model rats. CDCA treatment also attenuated 6-OHDA-induced neurotoxicity in vivo. To elucidate the underlying mechanisms, a Transwell co-culture system consisting of enteroendocrine and neuronal cells was established. While CDCA did not exert a direct neuroprotective effect on neurons, it significantly stimulated glucagon-like peptide-1 (GLP-1) secretion. This effect was markedly suppressed by the TGR5 inhibitor (Triamterene). Importantly, the neuroprotective benefits of CDCA were abolished by the GLP-1 receptor (GLP-1R) antagonist Exendin (9-39), confirming the necessity of the TGR5-GLP-1-GLP-1R signaling cascade. Collectively, these findings suggest that L. reuteri may exert neuroprotective effects by modulating bile acid metabolism, particularly CDCA, and potentially involving the TGR5-GLP-1R axis. This study highlights a possible gut microbiota-bile acid-brain axis and provides a basis for microbiota-based therapeutic strategies in PD.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Key Laboratory of Basic Pharmacology of Ministry of Education and Joint International Research Laboratory of Ethnomedicine of Ministry of Education and Key Laboratory of Basic Pharmacology of Guizhou Province and Labora…
- State Key Laboratory of Discovery and Utilization of Functional Components in Traditional Chinese Medicine, Guizhou Medical University, Guiyang, Guizhou, 561113, China. zhangfengzmc@163.com.
Förderung
- Zunyi Science and Technology Bureau
- Doctor Start Fund of Zunyi Medical University
- Guizhou Provincial Basic Research Programme(Natural Science)
- Guizhou Provincial Health Commission Science and Technology Fund
- the National Natural Science Foundation of China
- Science and Technology Foundation of Guizhou Province
- Guizhou Provincial Basic Research Programm
Zitieren
APA
Li, D., Gong, J., Sun, Z., Wang, G., & Zhang, F. (2026). Limosilactobacillus reuteri Alleviates Parkinson’s Disease by Regulating CDCA Secretion. Probiotics and Antimicrobial Proteins. https://doi.org/10.1007/s12602-026-11121-8
Vancouver
Li D, Gong J, Sun Z, Wang G, Zhang F. Limosilactobacillus reuteri Alleviates Parkinson’s Disease by Regulating CDCA Secretion. Probiotics and Antimicrobial Proteins. 2026. doi:10.1007/s12602-026-11121-8
BibTeX
@article{Li2026,
author = {Li, Daidi and Gong, Jiantao and Sun, Zhongxian and Wang, Guoqing and Zhang, Feng},
title = {Limosilactobacillus reuteri Alleviates Parkinson’s Disease by Regulating CDCA Secretion},
journal = {Probiotics and Antimicrobial Proteins},
year = {2026},
doi = {10.1007/s12602-026-11121-8}
}
EUVIMED